La Trobe
1175031_Marx,W_2021.pdf (197.47 kB)

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

Download (197.47 kB)
journal contribution
posted on 03.08.2021, 03:04 by Wolfgang MarxWolfgang Marx, David R Skvarc, Mohammadreza Mohebbi, Adam J Walker, Alcy Meehan, Alyna Turner, Andrea Baker, Seetal Dodd, Sue M Cotton, James Graham Scott, Bianca E Kavanagh, Melanie M Ashton, Ellie Brown, John J McGrath, Michael Berk, Olivia May Dean
Background: Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive performance in this population.Methods: This was a secondary analysis of a larger randomized placebo-controlled trial that investigated a 24-weeks intervention of mangosteen pericarp extract supplementation in people diagnosed with schizophrenia. A subset of n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes.Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change.Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.Trial Registration:ANZCTR.org.au identifier: ACTRN12616000859482, registered 30 June 3 2016.

Funding

The primary study was funded by the Stanley Medical Research Institute (Treatment Trial #14T-007). All authors gratefully acknowledge their support. We wish to thank the participants who took part in the study, the health services including Barwon Health, the West Moreton Hospital and Health Service, the Metro North Mental Health Service, Metro South Mental Health Service, Gold Coast Mental Health Service, the Melbourne Clinic and the Community and Research Network. MB was supported by a NHMRC Senior Principal Research Fellowship 1059660 and 1156072. JM was supported by grant APP1056929 from the John Cade Fellowship from the National Health and Medical Research Council. OD was supported by a NHMRC R.D. Wright Career Development Fellowship (1145634).

History

Publication Date

15/06/2021

Journal

FRONTIERS IN PSYCHIATRY

Volume

12

Article Number

ARTN 626486

Pagination

8p.

Publisher

FRONTIERS MEDIA SA

ISSN

1664-0640

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.